Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study.

Lu C, Chen Y, Zhang B, Chen Y, Bai F, Chen D

Clinical interventions in aging12 Oct 2017Cited by 6 (Europe PMC)

PMID29066877PMCIDPMC5644555DOI10.2147/cia.s140900PepBankPUB-29066877

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, teriparatide increased lumbar spine BMD more than calcitonin at week 24.
In plain wordsIn postmenopausal women, teriparatide increased lumbar spine bone density more than calcitonin at week 24.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n: not reported in source
Comparator
Calcitonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Teriparatide treatment produced a significantly greater increase in lumbar spine bone-mineral density (LS-BMD) in postmenopausal women than calcitonin at the 24-week end point.
1 context sentence(design, population, supporting numbers)
Summary · context
In this Phase III study of teriparatide in China, 362 patients were randomized at a 2:1 ratio to receive subcutaneous teriparatide (20 μg/day) or intranasal salmon calcitonin (200 IU/day) for 24 weeks.
Report a problemFND-2906687701
02HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, 81% receiving teriparatide versus 6% receiving calcitonin achieved an osteocalcin increase above 10 μg/L at week 12.
In plain wordsMore osteoporosis patients receiving teriparatide than calcitonin achieved an osteocalcin increase above the specified threshold at week 12.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteocalcin response above threshold
Study
n: not reported in source
Comparator
Calcitonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Proportion with osteocalcin change >10 μg/L
81%
teriparatide, week 12
Proportion with osteocalcin change >10 μg/L
6%
calcitonin, week 12
Source sentences
Summary
Proportions of patients achieving >10 μg/L absolute OCN change from baseline in the teriparatide- and calcitonin-treated groups were 81% and 6% at week 12, respectively (P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this Phase III study of teriparatide in China, 362 patients were randomized at a 2:1 ratio to receive subcutaneous teriparatide (20 μg/day) or intranasal salmon calcitonin (200 IU/day) for 24 weeks.
Report a problemFND-2906687704
03HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, 71% receiving teriparatide versus 35% receiving calcitonin achieved at least 3% lumbar spine BMD increase at week 24.
In plain wordsMore osteoporosis patients receiving teriparatide than calcitonin achieved at least 3% lumbar spine bone density increase at week 24.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD response at least 3%
Study
n: not reported in source
Comparator
Calcitonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Proportion with LS-BMD increase ≥3%
71%
teriparatide, week 24
Proportion with LS-BMD increase ≥3%
35%
calcitonin, week 24
Source sentences
Summary
Proportions of patients with increased LS-BMD ≥3% at week 24 from baseline were 71% and 35% in the teriparatide- and calcitonin-treated groups, respectively (P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this Phase III study of teriparatide in China, 362 patients were randomized at a 2:1 ratio to receive subcutaneous teriparatide (20 μg/day) or intranasal salmon calcitonin (200 IU/day) for 24 weeks.
Report a problemFND-2906687705
04HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, 63% receiving teriparatide versus 1% receiving calcitonin met both osteocalcin and lumbar spine BMD response criteria.
In plain wordsMore osteoporosis patients receiving teriparatide than calcitonin met both the osteocalcin and bone density response criteria.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCombined osteocalcin and BMD response
Study
n: not reported in source
Comparator
Calcitonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Proportion meeting both osteocalcin and LS-BMD criteria
63%
teriparatide
Proportion meeting both osteocalcin and LS-BMD criteria
1%
calcitonin
Source sentences
Summary
Proportions of patients meeting both criteria were 63% for the teriparatide group and 1% for the calcitonin-treated group (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Proportions of patients achieving >10 μg/L absolute OCN change from baseline in the teriparatide- and calcitonin-treated groups were 81% and 6% at week 12, respectively (P<0.001). Proportions of patients with increased LS-BMD ≥3% at week 24 from baseline were 71% and 35% in the teriparatide-…
Summary · context
In this Phase III study of teriparatide in China, 362 patients were randomized at a 2:1 ratio to receive subcutaneous teriparatide (20 μg/day) or intranasal salmon calcitonin (200 IU/day) for 24 weeks.
Report a problemFND-2906687706

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In teriparatide-treated patients, absolute osteocalcin change at week 12 correlated positively with percentage lumbar spine BMD change.
In plain wordsIn teriparatide-treated patients, osteocalcin change at week 12 was linked to lumbar spine bone density change.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseWeek 12 osteocalcin change correlation with BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Correlation
0.24 r
week 12 osteocalcin change
Source sentences
Summary
The relationship between osteocalcin (OCN) and LS-BMD was evaluated, and the greatest correlation was found between absolute OCN change at week 12 and percentage change in LS-BMD for patients in the teriparatide group (r=0.24, P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this Phase III study of teriparatide in China, 362 patients were randomized at a 2:1 ratio to receive subcutaneous teriparatide (20 μg/day) or intranasal salmon calcitonin (200 IU/day) for 24 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2906687702
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In teriparatide-treated patients, the osteocalcin correlation with lumbar spine BMD weakened at week 24 but remained positive.
In plain wordsIn teriparatide-treated patients, the link between osteocalcin and bone density was weaker at week 24.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseWeek 24 osteocalcin correlation with BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Correlation
0.16 r
week 24
Source sentences
Summary
The correlation weakened at week 24 (r=0.16, P=0.02) and was negligibly negative for calcitonin-treated patients.
2 context sentences(design, population, supporting numbers)
Summary · context
The relationship between osteocalcin (OCN) and LS-BMD was evaluated, and the greatest correlation was found between absolute OCN change at week 12 and percentage change in LS-BMD for patients in the teriparatide group (r=0.24, P<0.001).
Summary · context
In this Phase III study of teriparatide in China, 362 patients were randomized at a 2:1 ratio to receive subcutaneous teriparatide (20 μg/day) or intranasal salmon calcitonin (200 IU/day) for 24 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2906687703
07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporosis patients receiving teriparatide, lumbar spine BMD increased significantly regardless of baseline age, BMD, and fracture times.
In plain wordsIn osteoporosis patients receiving teriparatide, lumbar spine bone density increased across baseline age, bone density, and fracture subgroups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD across baseline subgroups
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Subgroup analysis suggested that significant increases in LS-BMD and OCN can be achieved in patients receiving teriparatide, regardless of baseline age, LS-BMD, and fracture times.
1 context sentence(design, population, supporting numbers)
Summary · context
In this Phase III study of teriparatide in China, 362 patients were randomized at a 2:1 ratio to receive subcutaneous teriparatide (20 μg/day) or intranasal salmon calcitonin (200 IU/day) for 24 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2906687707
08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In osteoporosis patients receiving teriparatide, osteocalcin increased significantly regardless of baseline age, lumbar spine BMD, and fracture times.
In plain wordsIn osteoporosis patients receiving teriparatide, osteocalcin increased across baseline age, bone density, and fracture subgroups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteocalcin across baseline subgroups
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Subgroup analysis suggested that significant increases in LS-BMD and OCN can be achieved in patients receiving teriparatide, regardless of baseline age, LS-BMD, and fracture times.
1 context sentence(design, population, supporting numbers)
Summary · context
In this Phase III study of teriparatide in China, 362 patients were randomized at a 2:1 ratio to receive subcutaneous teriparatide (20 μg/day) or intranasal salmon calcitonin (200 IU/day) for 24 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2906687708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study.

Summary

Results from this study8

Studies that did not test the peptide alone4

Version history

Subjects

Publication types

MeSH terms

Keywords